Bradley Canino
Stock Analyst at Stifel
(1.03)
# 3,467
Out of 4,810 analysts
94
Total ratings
24.69%
Success rate
-14.98%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Bradley Canino
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BDTX Black Diamond Therapeutics | Maintains: Buy | $16 → $15 | $1.42 | +956.34% | 5 | Mar 7, 2025 | |
| ALXO ALX Oncology Holdings | Maintains: Hold | $3 → $1.5 | $0.55 | +175.13% | 8 | Mar 7, 2025 | |
| RLAY Relay Therapeutics | Maintains: Buy | $27 → $23 | $2.76 | +733.33% | 5 | Feb 27, 2025 | |
| ARVN Arvinas | Maintains: Buy | $63 → $51 | $7.58 | +572.82% | 6 | Feb 12, 2025 | |
| JANX Janux Therapeutics | Maintains: Buy | $70 → $115 | $29.06 | +295.73% | 2 | Dec 3, 2024 | |
| AFMD Affimed | Maintains: Hold | $5 → $4 | $0.72 | +454.79% | 5 | Nov 15, 2024 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $40 → $41 | $11.33 | +261.87% | 5 | Oct 14, 2024 | |
| KURA Kura Oncology | Downgrades: Hold | $26 → $19 | $6.03 | +215.09% | 6 | Oct 14, 2024 | |
| CELC Celcuity | Maintains: Buy | $39 → $42 | $10.11 | +315.43% | 4 | Oct 7, 2024 | |
| SMMT Summit Therapeutics | Maintains: Buy | $25 → $40 | $24.62 | +62.47% | 4 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $115 → $135 | $70.78 | +90.73% | 4 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $5.04 | +296.83% | 1 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $0.92 | +992.90% | 1 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $10 | $1.27 | +687.40% | 17 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $99 | $43.22 | +129.06% | 7 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $14 | $1.19 | +1,076.47% | 4 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $40 | $7.80 | +412.82% | 1 | May 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $130 | $81.45 | +59.61% | 5 | Apr 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $55 | $25.46 | +116.03% | 4 | Feb 23, 2024 |
Black Diamond Therapeutics
Mar 7, 2025
Maintains: Buy
Price Target: $16 → $15
Current: $1.42
Upside: +956.34%
ALX Oncology Holdings
Mar 7, 2025
Maintains: Hold
Price Target: $3 → $1.5
Current: $0.55
Upside: +175.13%
Relay Therapeutics
Feb 27, 2025
Maintains: Buy
Price Target: $27 → $23
Current: $2.76
Upside: +733.33%
Arvinas
Feb 12, 2025
Maintains: Buy
Price Target: $63 → $51
Current: $7.58
Upside: +572.82%
Janux Therapeutics
Dec 3, 2024
Maintains: Buy
Price Target: $70 → $115
Current: $29.06
Upside: +295.73%
Affimed
Nov 15, 2024
Maintains: Hold
Price Target: $5 → $4
Current: $0.72
Upside: +454.79%
Syndax Pharmaceuticals
Oct 14, 2024
Maintains: Buy
Price Target: $40 → $41
Current: $11.33
Upside: +261.87%
Kura Oncology
Oct 14, 2024
Downgrades: Hold
Price Target: $26 → $19
Current: $6.03
Upside: +215.09%
Celcuity
Oct 7, 2024
Maintains: Buy
Price Target: $39 → $42
Current: $10.11
Upside: +315.43%
Summit Therapeutics
Sep 25, 2024
Maintains: Buy
Price Target: $25 → $40
Current: $24.62
Upside: +62.47%
Sep 16, 2024
Maintains: Buy
Price Target: $115 → $135
Current: $70.78
Upside: +90.73%
Sep 6, 2024
Initiates: Buy
Price Target: $20
Current: $5.04
Upside: +296.83%
Aug 8, 2024
Initiates: Buy
Price Target: $10
Current: $0.92
Upside: +992.90%
Jun 18, 2024
Maintains: Buy
Price Target: $32 → $10
Current: $1.27
Upside: +687.40%
Jun 17, 2024
Maintains: Buy
Price Target: $90 → $99
Current: $43.22
Upside: +129.06%
May 9, 2024
Maintains: Buy
Price Target: $13 → $14
Current: $1.19
Upside: +1,076.47%
May 1, 2024
Initiates: Buy
Price Target: $40
Current: $7.80
Upside: +412.82%
Apr 26, 2024
Maintains: Buy
Price Target: $120 → $130
Current: $81.45
Upside: +59.61%
Feb 23, 2024
Maintains: Buy
Price Target: $35 → $55
Current: $25.46
Upside: +116.03%